Edlund, P. et al. 2011. Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. Acta Oncologica. 50, 3 (Apr. 2011), 329–337. DOI:https://doi.org/10.3109/0284186X.2011.554435.